As a potential treatment of COVID-19: Montelukast #MMPMID32416408
Fidan C; Aydogdu A
Med Hypotheses 2020[Sep]; 142 (ä): 109828 PMID32416408show ga
It has been hypothesized that Montelukast, a cysteinyl leukotriene (cysLT) receptor antagonist, with effects of anti-inflammatory, suppress oxidative stress and reduce affect cytokine production, may limited progression of the disease on COVID-19 infection.